The researchers utilized a cost-minimization decision tree model, a budget impact analysis and physician surveys to compare the economic values.
Here are five points:
1. A budget impact analysis estimated that when the cost savings are amortized over one million lives, IBSchek will save healthcare payers more than $3.5 million annually.
2. A cost-minimization decision tree model predicted an estimated a $509 cost saving with use of IBSchek versus the exclusionary diagnostic pathway, which is the current standard of care.
3. Additionally, the exclusionary diagnostic pathway used in this study did not consider repeated investigations, the potential for more invasive studies stemming from false-positive results of the investigations or the cost of pathology assessments.
4. Salem, Mass.-based Commonwealth Laboratories developed IBSchek.
5. Commonwealth Laboratories is an independent diagnostic laboratory offering specialized diagnostic tests to aid in the diagnosis of a variety of functional gastrointestinal disorders.
More articles on GI & endoscopy:
Takeda acquires license for GI motility disorders medication for $15M: 5 things to know
Olympus introduces new aspiration needle, EndoChoice short interest jumps 6.36% — 4 GI company key notes
AGA names Dr. Richard Boland 2016 Julius Friedenwald Medal winner: 6 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
